Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 25;35(8):109165.
doi: 10.1016/j.celrep.2021.109165.

Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics

Affiliations
Free article

Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics

Susan Olalekan et al. Cell Rep. .
Free article

Abstract

Understanding the cellular composition of the tumor microenvironment and the interactions of the cells is essential to the development of successful immunotherapies in cancer. We perform single-cell RNA sequencing (scRNA-seq) of 9,885 cells isolated from the omentum in 6 patients with ovarian cancer and identify 9 major cell types, including cancer, stromal, and immune cells. Transcriptional analysis of immune cells stratifies our patient samples into 2 groups: (1) high T cell infiltration (high Tinf) and (2) low T cell infiltration (low Tinf). TOX-expressing resident memory CD8+ T (CD8+ Trm) and granulysin-expressing CD4+ T cell clusters are enriched in the high Tinf group. Concurrently, we find unique plasmablast and plasma B cell clusters, and finally, NR1H2+IRF8+ and CD274+ macrophage clusters, suggesting an anti-tumor response in the high Tinf group. Our scRNA-seq study of metastatic tumor samples provides important insights in elucidating the immune response within ovarian tumors.

Keywords: human cancer; immune cells; metastasis; ovarian cancer; scRNA-seq; solid tumor; transcriptomics.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.B. is a consultant for Novartis Institutes for BioMedical Research. All of the other authors declare no competing interests.

Publication types